title: A case of bullous pemphigoid ınduced by vildagliptin.
abstract: Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature. We report a patient with BP in which vildagliptin was thought to be as a possible causative agent. The awareness of BP development risk during gliptin therapy can prevent unnecessary usage of systemic drugs with serious side effects.
authors.affiliation: a Department of Dermatology , Dışkapı Yıldırım Beyazıt Education and Research Hospital , Ankara , Turkey.
authors.forename: Havva Ozge
authors.initials: HO
authors.lastname: Keseroglu
authors.affiliation: a Department of Dermatology , Dışkapı Yıldırım Beyazıt Education and Research Hospital , Ankara , Turkey.
authors.forename: Gamze
authors.initials: G
authors.lastname: Taş-Aygar
authors.affiliation: a Department of Dermatology , Dışkapı Yıldırım Beyazıt Education and Research Hospital , Ankara , Turkey.
authors.forename: Müzeyyen
authors.initials: M
authors.lastname: Gönül
authors.affiliation: b Department of Pathology , and.
authors.forename: Ozay
authors.initials: O
authors.lastname: Gököz
authors.affiliation: c Department of Dermatology , Faculty of Medicine, Hacettepe University , Ankara , Turkey.
authors.forename: Sibel
authors.initials: S
authors.lastname: Ersoy-Evans
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000279:Administration, Cutaneous; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use; D003176:Complement C3 / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D005907:Gliclazide / Q000627:therapeutic use; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D011759:Pyrrolidines / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000276:immunology / Q000473:pathology; D000077597:Vildagliptin; D028761:Withholding Treatment
chemical_list: D003176:Complement C3; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005938:Glucocorticoids; D007004:Hypoglycemic Agents; D009570:Nitriles; D011759:Pyrrolidines; D008687:Metformin; D002990:Clobetasol; D005907:Gliclazide; D000077597:Vildagliptin; D000218:Adamantane
keywords: Bullous pemphigoid; gliptins; vildagliptin